- Home
- BOOT vs ICUI Comparison
BOOT vs ICUI Comparison
Compare BOOT & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOOT
- ICUI
- Stock Information
- Founded
- BOOT 1978
- ICUI 1984
- Country
- BOOT United States
- ICUI United States
- Employees
- BOOT N/A
- ICUI N/A
- Industry
- BOOT Clothing/Shoe/Accessory Stores
- ICUI Medical/Dental Instruments
- Sector
- BOOT Consumer Discretionary
- ICUI Health Care
- Exchange
- BOOT Nasdaq
- ICUI Nasdaq
- Market Cap
- BOOT 4.1B
- ICUI 4.0B
- IPO Year
- BOOT 2014
- ICUI 1992
- Fundamental
- Price
- BOOT $151.47
- ICUI $164.78
- Analyst Decision
- BOOT Strong Buy
- ICUI Buy
- Analyst Count
- BOOT 11
- ICUI 4
- Target Price
- BOOT $138.20
- ICUI $138.33
- AVG Volume (30 Days)
- BOOT 434.8K
- ICUI 257.7K
- Earning Date
- BOOT 10-31-2024
- ICUI 11-04-2024
- Dividend Yield
- BOOT N/A
- ICUI N/A
- EPS Growth
- BOOT N/A
- ICUI N/A
- EPS
- BOOT 4.93
- ICUI N/A
- Revenue
- BOOT $1,706,700,000.00
- ICUI $2,304,277,000.00
- Revenue This Year
- BOOT $12.90
- ICUI $3.80
- Revenue Next Year
- BOOT $13.97
- ICUI $4.01
- P/E Ratio
- BOOT $28.16
- ICUI N/A
- Revenue Growth
- BOOT 1.86
- ICUI 0.46
- 52 Week Low
- BOOT $66.73
- ICUI $78.28
- 52 Week High
- BOOT $143.57
- ICUI $167.78
- Technical
- Relative Strength Index (RSI)
- BOOT 74.73
- ICUI 68.73
- Support Level
- BOOT $133.59
- ICUI $160.74
- Resistance Level
- BOOT $137.56
- ICUI $167.78
- Average True Range (ATR)
- BOOT 4.05
- ICUI 3.81
- MACD
- BOOT 0.96
- ICUI -0.94
- Stochastic Oscillator
- BOOT 99.96
- ICUI 80.34
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.